Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9779699rdf:typepubmed:Citationlld:pubmed
pubmed-article:9779699lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C0239307lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C0024305lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C1522326lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C1096776lld:lifeskim
pubmed-article:9779699lifeskim:mentionsumls-concept:C1178562lld:lifeskim
pubmed-article:9779699pubmed:issue10lld:pubmed
pubmed-article:9779699pubmed:dateCreated1998-10-26lld:pubmed
pubmed-article:9779699pubmed:abstractTextCAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B-cell and T-cell lymphomas. We report here the results of a multicenter phase II trial of CAMPATH-1H in patients with advanced, low-grade non-Hodgkin's lymphoma (NHL) who were previously treated with chemotherapy.lld:pubmed
pubmed-article:9779699pubmed:languageenglld:pubmed
pubmed-article:9779699pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:citationSubsetIMlld:pubmed
pubmed-article:9779699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9779699pubmed:statusMEDLINElld:pubmed
pubmed-article:9779699pubmed:monthOctlld:pubmed
pubmed-article:9779699pubmed:issn0732-183Xlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:MarcusRRlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:ThomasJJlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:CrowtherDDlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:WillemzeRRlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:HuhnDDlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:BrittingerGGlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:MellstedtHHlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:GisselbrechtC...lld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:JaegerUUlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:PoyntonCClld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:EngertAAlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:LundinJJlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:NisselHHlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:StahelRRlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:DombretHHlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:UppenkampMMlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:EpenetosAAlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:OsterborgAAlld:pubmed
pubmed-article:9779699pubmed:authorpubmed-author:RankinEElld:pubmed
pubmed-article:9779699pubmed:issnTypePrintlld:pubmed
pubmed-article:9779699pubmed:volume16lld:pubmed
pubmed-article:9779699pubmed:ownerNLMlld:pubmed
pubmed-article:9779699pubmed:authorsCompleteYlld:pubmed
pubmed-article:9779699pubmed:pagination3257-63lld:pubmed
pubmed-article:9779699pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:meshHeadingpubmed-meshheading:9779699-...lld:pubmed
pubmed-article:9779699pubmed:year1998lld:pubmed
pubmed-article:9779699pubmed:articleTitleCAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.lld:pubmed
pubmed-article:9779699pubmed:affiliationDepartment of Oncology, Karolinska Hospital, Stockholm, Sweden.lld:pubmed
pubmed-article:9779699pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9779699pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9779699pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:9779699pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:9779699pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9779699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9779699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9779699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9779699lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9779699lld:pubmed